Financial Position - As of December 31, 2025, MapLight Therapeutics, Inc. reported cash and cash equivalents of approximately $450 million[6] - The preliminary cash and cash equivalents figure is subject to change upon completion of the financial closing procedures and the preparation of audited financial statements[7] - The financial information provided is preliminary and has not been audited, indicating potential variations from actual financial results[7] - The corporate presentation includes selected preliminary financial information for the fiscal year ended December 31, 2025[6] Clinical Trials - The company announced that topline results from its ongoing Phase 2 ZEPHYR and IRIS clinical trials are now expected in the third quarter of 2026[9] - The press release regarding the update on clinical trial results was issued on January 9, 2026[9] Corporate Governance - MapLight Therapeutics is classified as an emerging growth company under the Securities Act[5] - The company has not elected to use the extended transition period for complying with new or revised financial accounting standards[5] - The independent registered public accounting firm has not conducted an audit or review of the preliminary estimate provided[7] Investor Relations - The company updated its corporate presentation for investor meetings, which is available on its website[10]
MapLight Therapeutics(MPLT) - 2025 Q4 - Annual Results